Part 2 of 4: Uncertainties and controversies in neurology and medicine - with focus on cardio and cerebrovascular disease, stroke and TIAs. Future Rife with Strife series will focus on controversies in other areas of neurology.

Today’s focus: EDTA (ethyline diamine tetra acetate) for the treatment of cardiac, peripheral and cerebral atherosclerosis.

Reports:

• Basics of EDTA pharmacology
• History of EDTA as a treatment for atherosclerosis
• Trial to Assess Chelation Therapy (TACT)
• Controversies of EDTA chelation for treating atherosclerosis. E.g. U.S. vs. Evers.

Resources for learning more:

• www.drcranton.com/chelation.htm
• www.acam.org
• Saunders textbook: Cardiovascular Drug Therapy - with chapter and many references on EDTA chelation therapy.

Who are the ‘Quackbusters‘? We didn’t have time to cover this question during the show, but this group remains a mystery. It publishes opinions against so-called ‘integrative medicine’ (previously called ‘alternative medicine’), including attacks against the use of EDTA chelation for atherosclerosis. We on the STAT editorial team would appreciate learning who funds this organization. It is not clear from their website.
Next week’s show: We’ll address testosterone for stroke care and the controversial area of bio-identical hormone therapy (versus the use of synthetic/derivatized hormones).

Flow Productions will be producing additional lines of podcasts based on cutting medical news and information. Click for demos: Audio magazine format and video (’enhanced podcast’). If you are interested in sponsoring one of the shows please contact info@flowproductions.org.

 

 Standard Podcast [27:04m]: Play Now | Play in Popup | Download